Substance Use Disorder Treatment Services in the United States

Substance use disorder (SUD) treatment services in the United States encompass a structured continuum of clinical, behavioral, and supportive interventions designed to address dependence on alcohol, opioids, stimulants, cannabis, and other substances. Federal oversight is distributed across multiple agencies, including the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA), with coverage mandates shaped by the Affordable Care Act and parity law. This page defines the scope of SUD treatment, explains how service delivery is organized, identifies common clinical scenarios, and clarifies the decision boundaries that determine appropriate level of care. Understanding this framework is foundational for navigating the behavioral health integration landscape in the United States.

Definition and scope

Substance use disorder is classified as a mental health condition under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association (APA). The DSM-5 defines SUD along a severity continuum — mild, moderate, or severe — based on the number of diagnostic criteria met across 11 categories, ranging from loss of control over use to social impairment and pharmacological tolerance (APA DSM-5).

Federal scope is defined primarily through two statutes:

• 42 U.S.C. § 290bb-25 establishes SAMHSA's authority to fund and regulate SUD treatment programs.
• The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that health insurance plans offering SUD benefits apply the same coverage standards as for medical and surgical conditions (U.S. Department of Labor, MHPAEA).

SUD treatment is further governed by state licensure requirements administered through each state's single state agency (SSA) for substance abuse, a structure mandated under the Substance Abuse Prevention and Treatment (SAPT) Block Grant program. As of the 2023 SAMHSA National Survey on Drug Use and Health (NSDUH 2023), approximately 48.7 million Americans aged 12 or older met criteria for a substance use disorder in the past year, yet fewer than 1 in 4 received any form of specialty treatment.

SUD services intersect with mental health services and chronic disease management programs, reflecting the clinical reality that SUD frequently co-occurs with mood disorders, trauma-related conditions, and metabolic disease.

How it works

SUD treatment is organized according to the ASAM Criteria (formerly the American Society of Addiction Medicine Patient Placement Criteria), a nationally recognized framework that assigns patients to one of six levels of care based on a multidimensional assessment (ASAM Criteria, 4th Edition):

1. Level 0.5 — Early Intervention: Targeted education and screening for individuals at risk but not yet diagnosable.
2. Level 1 — Outpatient Services: Fewer than 9 hours of structured treatment per week; appropriate for mild SUD without significant withdrawal risk.
3. Level 2.1 — Intensive Outpatient Program (IOP): 9 or more hours of structured programming per week; group and individual counseling without overnight stay.
4. Level 2.5 — Partial Hospitalization Program (PHP): 20 or more hours per week; near-daily structured treatment with medical monitoring.
5. Level 3 — Residential/Inpatient: 24-hour supervised care ranging from clinically managed low-intensity (3.1) to medically managed intensive inpatient (3.7).
6. Level 4 — Medically Managed Intensive Inpatient: Hospital-based care for severe withdrawal, co-occurring acute medical conditions, or psychiatric emergencies.

Placement decisions integrate six ASAM dimensions: acute intoxication and withdrawal potential, biomedical conditions, emotional and cognitive conditions, readiness to change, relapse or continued use potential, and recovery environment.

Medication-Assisted Treatment (MAT) is a core modality at multiple levels. The FDA has approved three medications for opioid use disorder (OUD) — methadone, buprenorphine, and naltrexone — and two for alcohol use disorder (AUD): naltrexone and acamprosate (FDA, Opioid Use Disorder Medications). Methadone for OUD is dispensed exclusively through federally certified Opioid Treatment Programs (OTPs) regulated under 42 CFR Part 8. Buprenorphine may be prescribed by any DEA-registered practitioner with a Schedule III controlled substance prescribing authority. The Consolidated Appropriations Act, 2023 (Pub. L. 117-328, enacted December 29, 2022) permanently eliminated the separate DATA 2000 waiver (X-waiver) requirement effective January 1, 2023. Under current law, practitioners no longer need to obtain or maintain an X-waiver to prescribe buprenorphine for OUD; they must hold a valid DEA registration authorizing Schedule III controlled substance prescribing and comply with applicable federal and state practice standards. All patient limit requirements previously imposed under the X-waiver framework were also eliminated. This change materially expanded the pool of eligible prescribers across primary care, emergency medicine, and other non-specialty settings (SAMHSA, Buprenorphine).

Behavioral therapies operating across all levels include Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and Contingency Management (CM), each with distinct evidence bases documented in SAMHSA's Treatment Improvement Protocols (TIPs).

Common scenarios

Four clinical scenarios account for the majority of SUD treatment encounters in the United States:

Opioid Use Disorder with Acute Withdrawal Risk
Patients presenting with physical opioid dependence require medical withdrawal management before or concurrent with initiation of long-term treatment. The Clinical Opiate Withdrawal Scale (COWS) is the standardized tool for quantifying withdrawal severity. Patients with COWS scores above 12 typically require at minimum Level 3.2 medically monitored residential treatment.

Alcohol Use Disorder with Co-occurring Medical Complications
Alcohol withdrawal carries mortality risk through delirium tremens (DTs) and seizures. The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) guides medical management. Patients scoring above 15 on the CIWA-Ar are generally managed at Level 3.7 or Level 4. This population frequently interfaces with rehabilitation services post-stabilization for liver disease or peripheral neuropathy.

Stimulant Use Disorder (Methamphetamine, Cocaine)
No FDA-approved pharmacotherapy exists for stimulant use disorder as of the 2023 SAMHSA formulary guidance, placing behavioral therapies — particularly Contingency Management — as the primary evidence-based intervention. Level 2.1 IOP is the most commonly utilized entry point for stimulant-specific treatment.

Co-occurring SUD and Psychiatric Disorder (Dual Diagnosis)
Approximately 21.5 million adults in the United States had co-occurring SUD and a mental illness in 2022 (SAMHSA NSDUH 2022). Integrated dual-diagnosis treatment (IDDT), which addresses both conditions within a single clinical encounter, is the standard of care per SAMHSA's Evidence-Based Practices Resource Center. These patients are commonly placed at Level 3.3 (clinically managed population-specific high-intensity residential) or Level 3.5 (clinically managed high-intensity residential).

Access to treatment varies significantly by geography. Rural healthcare access represents a structural barrier for residents outside metropolitan areas, where Level 3 and Level 4 services are concentrated. Federally Qualified Health Centers are a primary point of access for uninsured or underinsured individuals, as FQHCs receive SAMHSA SUD grants and are required to serve patients regardless of ability to pay.

Decision boundaries

Determining appropriate SUD treatment services involves a defined set of classification boundaries that distinguish levels, modalities, and coverage applicability.

Outpatient vs. Residential Treatment
ASAM Level 1 and Level 2 services are appropriate when a patient's withdrawal risk is low, social support is adequate, and the recovery environment does not pose immediate relapse risk. Residential services (Level 3) are indicated when any of the following conditions is present: high physiological withdrawal severity, prior failed outpatient treatment episodes, unstable housing, or active domestic violence in the home environment. This distinction also carries direct outpatient vs. inpatient care coverage implications under most commercial and public insurance plans.

MAT vs. Abstinence-Based Programming
MAT and abstinence-based approaches are not mutually exclusive but serve different clinical populations. Patients with moderate-to-severe OUD have documented higher retention and lower overdose mortality rates with MAT than with behavioral-only treatment, according to the National Institute on Drug Abuse (NIDA, Medications to Treat Opioid Use Disorder). Abstinence-based programs that exclude patients on prescribed buprenorphine or methadone may conflict with MHPAEA parity requirements and ADA protections for individuals in medically supervised recovery. The Consolidated Appropriations Act, 2023 (Pub. L. 117-328, enacted December 29, 2022) permanently eliminated the X-waiver requirement effective January 1, 2023. Any DEA-registered practitioner authorized to prescribe Schedule III controlled substances may now prescribe buprenorphine for OUD without any separate waiver, registration, or patient limit. Practitioners remain subject to applicable federal and state practice requirements. This change has reduced a longstanding structural access barrier and extended MAT availability across primary care, federally qualified health centers, emergency departments, and other non-specialty settings that previously lacked a sufficient number of waivered providers.

Coverage Classification under Federal Parity
The MHPAEA, as interpreted by the Departments of Labor, Health and Human Services, and Treasury in the 2024 final rule (Federal Register, Vol. 89, No. 71, April 2024), prohibits insurers from applying more restrictive prior authorization requirements, visit limits, or non-quantitative treatment limitations (NQTLs) to SUD benefits than those applied to analogous medical and surgical benefits.